Performance of an electrocardiographic analysis system: Implications for pharmacodynamic studies

Pharmacotherapy

Volumn 16, Issue 2 I, 1996, Pages 230-236

  Hoon, Timothy J ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANALYZER; ARTICLE; AUTOMATION; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; QRS COMPLEX; QT INTERVAL;

ADULT; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED;

EID: 0030005032     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Lalonde RL, Straka RJ, Pieper JA, Bottorff MB, Mirvis DM. Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers. J Pharmacokinet Biopharm 1987;15:569-82.
2. Lalonde RL, O'Rear TL, Wainer IW, Drda KD, Herring VL, Bottorff MB. Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition Clin Pharmacol Ther 1990;48:509-19
3. Tenero DM, Bottorff MB, Given BD, et al. Pharmacokinetics and pharmacodynamics of dilevalol. Clin Pharmacol Ther 1989;46:648-56.
4. Pomeranz B, Macaulay RJB, Caudill MA, et al. Assessment of autonomie function in humans by heart rate spectral analysis Am J Physiol 1985;248 H151-3.
5. Pagani M, Lombardi F, Guzzetti S, et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res 1986;59:178-93.
6. Lipsitz LA, Mietus J, Moody GB, Goldberger AL. Spectral characteristics of heart rate variability before and during postural tilt. Relations to aging and risk of syncope. Circulation 1990;81:1803-10.
7. Padrini R, Piovan D, Busa M, al-Bunni M, Maiolino P, Ferrari M. Pharmacodynamic variability of flecainide assessed by QRS changes. Clin Pharmacol Ther 1993;53:59-64.
8. Liem LB, Yee YG, Swerdlow CD, Kates RE. Pharmacodynamics of procainamide in patients with ventricular tachyarrhythmias. J Clin Pharmacol 1988;28:984-9.
9. Zoble RG, Kirsten EB, Brewington J. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia Clin Pharmacol Ther 1989,45:535-41.
10. Piergies AA, Ruo TI, Jansyn EM, Belknap SM, Atkinson AJ Jr. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation. Clin Pharmacol Ther 1987;42:107-12
11. Holford NH, Coates PE, Guentert TW, Riegelman S, Sheiner LB. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration-effect relationships. Br J Clin Pharmacol 1981;11.187-95.
12. Thibonnier M, Holford NH, Upton RA, Blume CD, Williams RL. Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man. J Pharmacokinet Biopharm 1984;12:559-73.
13. Le Coz F, Funck-Brentano C, Poirier JM, Kibleur Y, Mazoit FX, Jaillon P. Prediction of sotalol-induced maximum steady-state QTc prolongation from single-dose administration in healthy volunteers. Clin Pharmacol Ther 1992;52:417-26.
14. Schoen MD, Parker RB, Hoon TJ, Hariman RJ, Bauman JL, Beckman KJ. Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects. Am J Cardiol 1991;67:300-4
15. Hoon TJ, McCollam PL, Beckman KJ, Hariman RJ, Bauman JL. Impact of food on the pharmacokinetics and electrocardiographic effects of sustained release verapamil in normal subjects. Am J Cardiol 1992;70:1072-6.
16. Berk SI, Beckman K, Hoon TJ, et al. Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil. Pharmacotherapy 1992;12:33-9.
17. Reiter MJ, Shand DG, Pritchett ELC. Comparison of intravenous and oral verapamil dosing. Clin Pharmacol Ther 1982;32:711-20.
18. McAllister RG, Kirsten EB. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther 1982;31:418-25.
19. Boyd RA, Chin SK, Don-Pedro O, et al. The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clin Pharmacol Ther 1989;46:408-19.
20. Schwartz JB, Verotta D, Sheiner LB. Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions J Pharmacol Exp Ther 1989,251.1032-8.
21. Sarazan RD. Chronically instrumented conscious dog model in cardiovascular toxicology studies. Toxicol Methods 1993;3:195-211
22. Sarazan RD. Validation of a digital data acquisition and analysis system in a cardiovascular toxicology laboratory. Toxicol Methods 1994;4:274-91.
23. Sheiner L, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.
24. Zar JH. Biostatistical analysis, 2nd ed. Englewood Cliffs, NJ Prentice-Hall, 1984.